



Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.07.2024 6097529-00015 Date of first issue: 30.06.2020 6.0

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name Ivermectin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-: Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company **MSD**

20 Spartan Road

1619 Spartan, South Africa

Telephone +27119239300

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - single ex-H371: May cause damage to organs.

posure, Category 2

Specific target organ toxicity - repeated

exposure, Category 2

Short-term (acute) aquatic hazard, Cate-

Long-term (chronic) aquatic hazard, Cat-

egory 1

H373: May cause damage to organs through pro-

longed or repeated exposure.

H400: Very toxic to aquatic life.

H410: Very toxic to aquatic life with long lasting

effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word Warning



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 6.0 06.07.2024 6097529-00015 Date of first issue: 30.06.2020

Hazard statements : H371 May cause damage to organs.

H373 May cause damage to organs through prolonged or

repeated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

Response:

P308 + P311 IF exposed or concerned: Call a POISON

CENTER/ doctor. P391 Collect spillage.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Ivermectin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ivermectin	70288-86-7 274-536-0	Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	>= 1 - < 2,5
		M-Factor (Acute aquatic toxicity): 10.000 M-Factor (Chronic aquatic toxicity): 10.000	



Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
6.0	06.07.2024	6097529-00015	Date of first issue: 30.06.2020

2,6-Di-tert-butyl-p-cresol 128-37-0 204-881-4 Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	: 1
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do

so by medical personnel. Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause damage to organs.

May cause damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Ivermectin Formulation



Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 6097529-00015 Date of first issue: 30.06.2020 6.0 06.07.2024

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Personal precautions

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.





 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available



Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ivermectin	70288-86-7	TWA	30 μg/m3 (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 μg/100 cm2	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
2,6-Di-tert-butyl-p- cresol	Workers	Inhalation	Long-term systemic effects	3,5 mg/m3
	Workers	Dermal	Long-term systemic effects	0,5 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	0,86 mg/m3
	Consumers	Dermal	Long-term systemic effects	0,25 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0,25 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

	, ,	` '
Substance name	Environmental Compartment	Value
2,6-Di-tert-butyl-p-cresol	Fresh water	0,199 µg/l
	Intermittent use/release	0,02 μg/l
	Marine water	0,02 μg/l
	Sewage treatment plant	0,17 mg/l
	Fresh water sediment	0,0996 mg/kg dry
		weight (d.w.)
	Marine sediment	0,00996 mg/kg
		dry weight (d.w.)
	Soil	0,04769 mg/kg
		dry weight (d.w.)
	Oral (Secondary Poisoning)	8,33 mg/kg food

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 6.0 06.07.2024 6097529-00015 Date of first issue: 30.06.2020

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : oily

Colour : light yellow
Odour : characteristic
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

167,5 °C

Flash point : 219,2 °C

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : 0,88 - 0,92

Density : No data available



Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

Solubility(ies)

Water solubility : practically insoluble Partition coefficient: n- : Not applicable

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation

exposure Skin contact Ingestion



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 6.0 06.07.2024 6097529-00015 Date of first issue: 30.06.2020

Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Components:

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5,11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6.000 mg/kg

Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Ivermectin:

Species : Rabbit

Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 404



Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ivermectin:

Species : Rabbit

Result : Mild eye irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ivermectin:

Exposure routes : Dermal Species : Humans

Result : Does not cause skin sensitisation.

2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact
Species : Humans
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts

Result: negative



Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

Test Type: Mouse Lymphoma

Result: negative

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Ivermectin:

Species : Rat Application Route : Oral

NOAEL : 1,5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2,0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0,6 mg/kg body weight



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 6.0 06.07.2024 6097529-00015 Date of first issue: 30.06.2020

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse Application Route: Oral

Developmental Toxicity: NOAEL: 0,2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0,4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

STOT - single exposure

May cause damage to organs.

Components:

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated



Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

exposure.

2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentra-

tions of 100 mg/kg bw or less.

Repeated dose toxicity

Components:

Ivermectin:

 Species
 : Dog

 NOAEL
 : 0,5 mg/kg

 LOAEL
 : 1 mg/kg

 Application Route
 : Oral

 Exposure time
 : 14 Weeks

Target Organs : Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1,2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species : Rat

NOAEL : 0,4 mg/kg

LOAEL : 0,8 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : spleen, Bone marrow, Kidney

2,6-Di-tert-butyl-p-cresol:

Species : Rat

NOAEL : 25 mg/kg

Application Route : Ingestion

Exposure time : 22 Months

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination



Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

SECTION 12: Ecological information

12.1 Toxicity

Components:

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0,003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

icity)

10.000

M-Factor (Chronic aquatic

toxicity)

10.000

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0,57 mg/l

Exposure time: 96 h

Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,48 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0,24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

icity)

. .

Toxicity to microorganisms : EC50 : > 10.000 mg/l



Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

Exposure time: 3 h

Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,053 mg/l Exposure time: 30 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,316 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

M-Factor (Chronic aquatic

toxicity)

12.2 Persistence and degradability

Components:

Ivermectin:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 240 d

2,6-Di-tert-butyl-p-cresol:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 4,5 % Exposure time: 28 d

Method: OECD Test Guideline 301C

12.3 Bioaccumulative potential

Components:

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-

octanol/water

log Pow: 3,22

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 330 - 1.800

Partition coefficient: n-

octanol/water

: log Pow: 5,1

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of



Ivermectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 6.0
 06.07.2024
 6097529-00015
 Date of first issue: 30.06.2020

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

IATA : Environmentally hazardous substance, liquid, n.o.s.



Ivermectin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 06.07.2024 6097529-00015 Date of first issue: 30.06.2020 6.0

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN 9 9 **ADR RID** 9 **IMDG** 9 **IATA** 9

14.4 Packing group

ADN

Packing group Ш Classification Code M6 Hazard Identification Number : 90 Labels 9

ADR

Ш Packing group Classification Code M6 Hazard Identification Number : 90 Labels 9 Tunnel restriction code (-)

RID

Packing group Ш Classification Code M6 Hazard Identification Number : 90 Labels 9

IMDG

Packing group Ш Labels 9 F-A, S-F EmS Code

IATA (Cargo)

Packing instruction (cargo 964

aircraft)

Packing instruction (LQ) Y964 Packing group Ш

Labels Miscellaneous

IATA (Passenger)

Packing instruction (passen-964

ger aircraft)

Packing instruction (LQ) Y964 Packing group Ш

Labels Miscellaneous

14.5 Environmental hazards

Environmentally hazardous yes

ADR

Environmentally hazardous : yes



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 6.0 06.07.2024 6097529-00015 Date of first issue: 30.06.2020

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H300 : Fatal if swallowed.

H311 : Toxic in contact with skin.

H370 : Causes damage to organs if swallowed.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard



Ivermectin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 06.07.2024 6097529-00015 Date of first issue: 30.06.2020 6.0

Aquatic Chronic Long-term (chronic) aquatic hazard

STOT RE Specific target organ toxicity - repeated exposure STOT SE Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified: NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

compile the Safety Data Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

STOT SE 2 Calculation method H371 STOT RE 2 H373 Calculation method Aquatic Acute 1 H400 Calculation method Aquatic Chronic 1 H410 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 6.0 06.07.2024 6097529-00015 Date of first issue: 30.06.2020

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN